Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Deferred Revenue (2018 - 2025)

Bicycle Therapeutics' Current Deferred Revenue history spans 8 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 70.94% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, down 70.94%, while the annual FY2025 figure was $3.0 million, 70.94% down from the prior year.
  • Current Deferred Revenue reached $3.0 million in Q4 2025 per BCYC's latest filing, down from $12.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $135.2 million in Q4 2023 to a low of $700000.0 in Q4 2022.
  • Average Current Deferred Revenue over 5 years is $22.5 million, with a median of $12.4 million recorded in 2025.
  • Peak YoY movement for Current Deferred Revenue: plummeted 99.02% in 2022, then skyrocketed 19213.43% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $71.3 million in 2021, then tumbled by 99.02% to $700000.0 in 2022, then surged by 19213.43% to $135.2 million in 2023, then crashed by 92.46% to $10.2 million in 2024, then tumbled by 70.94% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Current Deferred Revenue are $3.0 million (Q4 2025), $12.3 million (Q3 2025), and $14.6 million (Q2 2025).